Vir Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. (Vir Bio) on February 26, 2026, reporting events occurring on February 25, 2026. The filing details the entry into a material definitive agreement for a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 17,647,059 shares of common stock.
- Offering Price: $8.50 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 2,647,058 additional shares.
- Expected Net Proceeds: Approximately $141.1 million (base case) or approximately $162.3 million (if over-allotment is fully exercised), after deducting underwriting discounts, commissions, and estimated expenses.
- Closing Date: Expected on February 27, 2026, subject to customary conditions.
- Underwriters: Goldman Sachs & Co. LLC, Leerink Partners LLC, Evercore Group L.L.C., and Barclays Capital Inc.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the company's ongoing operations.
Material Changes
The primary material change is the execution of the underwriting agreement to raise capital. This transaction will increase the company's share count and cash liquidity upon closing. No other material changes to financial position or operations are detailed in this specific report.
Outlook, Risks, and Management Commentary
The filing confirms the offering is expected to close on February 27, 2026. The transaction is subject to the satisfaction of customary closing conditions. The underwriting agreement includes customary representations, warranties, covenants, and indemnification obligations. No specific forward-looking guidance regarding product development or financial performance is included in this document.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected February 27, 2026).
- Confirm whether the underwriters exercise the over-allotment option for an additional 2,647,058 shares.
- Review the final net proceeds received after all transaction expenses are settled.
- Check subsequent filings for the updated share count and diluted ownership structure.